İçeriğe geç
akaturk Akademik ölçüm

Makale detayı · 2023

Association of OPRK1 rs963549 and rs997917 polymorphisms with opioid use disorder and with the symptoms of depression, anxiety, craving and withdrawal.

Pharmacogenomics

YÖKSİS OpenAlex SJR Q3 JCR Q3 Atıf 2 Yüzdelik 59.9% FWCI 0.4
Yıl
2023
ISSN
1462-2416
Tür
article

Veri kaynağı ayrımı

  • YÖKSİS YÖKSİS makale kaydı
  • OpenAlex OpenAlex zenginleştirmesi (özet, atıf, konular)

Özet

İngilizce (OpenAlex)

Aim: To evaluate the association between OPRK1 rs963549 and rs997917 and opioid use disorder (OUD) and related phenotypes. Methods: A sample of 208 individuals with (n = 100) and without (n = 108) OUD were enrolled. OPRK1 rs963549 and rs997917 were analyzed by PCR–RFLP. Craving, opioid withdrawal and the intensity of depressive and anxiety symptoms were measured by the appropriate scales. Results: OPRK1 rs963549 variation showed a trend of association with decreased opioid withdrawal. No significant associations were found between OPRK1 rs963549 and rs997917 polymorphisms and craving, depression or anxiety symptoms. Neither single OPRK1 SNPs nor OPRK1 haplotypes were associated with OUD. Conclusion: Our results could be useful for treatment failures of individuals who experience greater opioid withdrawal due to their OPRK1 rs963549 genotypes.

Konular

  • Pharmacogenetics and Drug Metabolism
  • Pharmacology and Obesity Treatment
  • Neurotransmitter Receptor Influence on Behavior

Birincil konu Pharmacogenetics and Drug Metabolism

Yazarlar

  1. SELİN ÖZKAN KOTİLOĞLU
  2. DİLEK AKYÜZLÜ ANKARA ÜNİVERSİTESİ
  3. ŞAFAK YALÇIN ŞAHİNER
  4. Nagihan Ayaz